CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

20th November 2020
Publication Quarterly Report Q3 2020
24th November 2020
Investor Call Quarterly Report Q3 2020
05th April 2021
Publication Quarterly Report Q4/FY 2020 unaudited
06th April 2021
Investor Call Quarterly Report Q4/FY 2020 unaudited
30th April 2021
Publication Quarterly Report FY 2020 audited
21st May 2021
Publication Quarterly Report Q1 2021
1st June 2021
Investor Call Quarterly Report Q1 2021
20th August 2021
Publication Quarterly Report Q2 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
19th November 2021
Publication Quarterly Report Q3 2021
30th November 2021
Investor Call Quarterly Report Q3 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

Investors Domain Investor Relations Press releases

11/19/2021

CHEPLAPHARM continues strong Growth

more chevron_right
Investors Domain Investor Relations Press releases

10/13/2021

CHEPLAPHARM signed deal

more chevron_right
Investor Relations Press releases

06/16/2021

CHEPLAPHARM invests in portfolio of anti-infectives

more chevron_right
Investors Domain

06/16/2021

CHEPLAPHARM invests in portfolio of anti-infectives

more chevron_right
Investors Domain

05/04/2021

CHEPLAPHARM continues on the road to success

more chevron_right
Investor Relations Press releases

05/04/2021

CHEPLAPHARM continues on the road to success

more chevron_right
Investors Domain

04/01/2021

Changes of Management Board per April

more chevron_right
Investor Relations Press releases

04/01/2021

Changes of Management Board per April

more chevron_right
Investor Relations Press releases

03/01/2021

Changes of CHEPLAPHARM Management Board per March

more chevron_right
Investors Domain

03/01/2021

Changes of Management Board

more chevron_right

Investor Relations topics

Back to top expand_less